Patents Examined by Maury Audet
  • Self-assembly of therapeutic agent-peptide nanostructures
    Patent number: 10098967
    Abstract: Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: October 16, 2018
    Assignees: Ohio State Innovation Foundation, Trustees of Boston University
    Inventors: Jonathan R. Parquette, Se Hye Kim, Mark W. Grinstaff, Jonah A. Kaplan
  • Method for preparing peptides by assembling multiple peptide fragments
    Patent number: 10072041
    Abstract: Method for preparing a peptide assembly of n fragments and n?1 amino acids bearing a thiol function, represented by the formula: A1-C1-A2-C2-A3- . . . -Ci?1-Ai- . . . -Cn?1-An??(I) in which A1, A2, A3, . . . Ai . . . , An are peptide fragments, C1, C2, C3 . . . Ci?1 . . . Cn?1 are amino acid residues bearing a thiol function, n is comprised between 3 and 50, and i is 2 to n, in which a peptide-thioester is prepared of formula: A1-SR (II) in which A1 is a peptide fragment and SR is an alkyl thioester residue, R being alkyl optionally substituted, starting from a bis(2-sulphanylethyl)amino peptide.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: September 11, 2018
    Assignees: Centre National de la Recherche Scientifique, Universite de Lille 1 Sciences et Technologies
    Inventors: Oleg Melnyk, Nathalie Ollivier, Reda Mhidia, Julien Dheur
  • Anti-inflammatory pharmaceutical products
    Patent number: 10072055
    Abstract: Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: September 11, 2018
    Assignee: Resother Pharma APS
    Inventors: Angelo P. Consalvo, Nozer M. Mehta, Mauro Perretti, Jesmond Dalli
  • Astexin peptides
    Patent number: 10072048
    Abstract: Provided are astexin-1, astexin-2 and astexin-3 lasso peptides, which are based on sequences identified in Asticaccaulis excentricus, and methods of making and using same. Astexin-1 is highly polar, in contrast to many lasso peptides that are primarily hydrophobic, and has modest antimicrobial activity against Caulobacter crescentus, a bacterium related to Asticaccaulis excentricus. The solution structure of astexin-1 was determined, revealing a unique topology that is stabilized by hydrogen bonding between segments of the peptide. Astexins-2 and -3 are intracellular lasso peptides.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: September 11, 2018
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: A. James Link, Mikhail O. Maksimov
  • Insulin receptor partial agonists
    Patent number: 10017556
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 10, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Self-assembled Fmoc-ff hydrogels
    Patent number: 10004828
    Abstract: Novel peptide-based hydrogels, composed of short aromatic peptides (e.g., homodipeptides of aromatic amino acid residues) are disclosed. The hydrogels are characterized by remarkable rigidity and biocompatibility. Further disclosed are uses of these hydrogels in applications such as tissue engineering, drug delivery, cosmetics, implantation, packaging and the like. Further disclosed are processes and kits for preparing these hydrogels.
    Type: Grant
    Filed: October 15, 2006
    Date of Patent: June 26, 2018
    Assignee: Romat at Tel-Aviv University Ltd.
    Inventors: Ehud Gazit, Assaf Mahler, Meital Reches
  • Use of hepcidin as a regulator of iron homeostasis
    Patent number: 10004784
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Human placental collagen compositions, and methods of making and using the same
    Patent number: 9974840
    Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: May 22, 2018
    Assignee: Celularity, Inc.
    Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
  • Polypeptides
    Patent number: 9957330
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN?LX16X17X18QX20?X21AFIX25X26LWD. The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: May 1, 2018
    Assignee: AFFIBODY AB
    Inventors: Lars Abrahmsén, Ingmarie Höidén-Guthenberg, Elin Gunneriusson
  • Peptides inhibiting cold-inducible RNA binding protein activity
    Patent number: 9957295
    Abstract: Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. Methods of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor are also described herein.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: May 1, 2018
    Assignee: The Feinstein Institute for Medical Research
    Inventor: Ping Wang
  • Bradykinin receptor modulators and use thereof
    Patent number: 9920096
    Abstract: The present invention relates generally to novel biological and purified peptides as bradykinin receptor modulators for use in the treatment and/or prevention of inflammatory diseases, pain, hyperalgesia, cardiovascular and/or cerebral ischemic diseases, in a subject in need thereof.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 20, 2018
    Inventor: Jair Ribeiro Chagas
  • Polypeptides, nucleic acids and uses thereof
    Patent number: 9902761
    Abstract: We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: February 27, 2018
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Bruno Reversade
  • Stabilized pharmaceutical formulations of insulin aspart
    Patent number: 9895423
    Abstract: Stabilized pharmaceutical formulations of insulin aspart are disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold
  • Mutated immunoglobulin-binding polypeptides
    Patent number: 9896486
    Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 20, 2018
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman, Goran Bauren
  • Tumor vascular disrupting agent polypeptide, gene, expression vector, and use thereof
    Patent number: 9896498
    Abstract: The present invention relates to a tumor vascular disrupting agent polypeptide, gene, expression vector, and use thereof. The tumor vascular disrupting agent polypeptide has the amino acid sequence as shown by SEQ ID NO: 1. The polypeptide comprises a truncated tissue factor (tTF) and a tumor-targeting molecule (pHLIP); the factor and the molecule are connected by 5 amino acids, thereby ensuring the function of each not being affected by the other; the fusion protein can be positioned to the surface of a tumor vascular endothelial cell by means of the pHLIP, and provides the blood coagulation feature of the tTF in a tumor vessel and forms a thrombus, thereby disrupting the blood supply to the tumor area and treating tumor. The polypeptide of the present invention is significant to the treatment of tumor, and can be used in medicines for treating tumors.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: February 20, 2018
    Assignee: Beijing Hua'an Innovation Biotechnology Co., Ltd.
    Inventors: Guangjun Nie, Suping Li, Yanhua Tian, Ying Zhao
  • Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
    Patent number: 9895424
    Abstract: Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives are disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold
  • Treating renal and liver dysfunction with TLR4 antagonists
    Patent number: 9889176
    Abstract: The present invention derives from the finding that increased levels of Toll like receptor 4 (TLR4) is associated with liver failure and renal dysfunction and/or brain dysfunction and that by decreasing TLR4 levels in vivo, the kidney and brain consequences of liver disease that are precipitated by superimposed infection or inflammation may be reduced. Accordingly, the invention provides TLR4 antagonists for use in a method of treating an individual suffering from liver disease presenting with renal or brain dysfunction.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: February 13, 2018
    Assignee: YAQRIT LIMITED
    Inventors: Rajiv Jalan, Naina Shah
  • Delivery of agents using interfering nanoparticles
    Patent number: 9878050
    Abstract: Provided are compositions and methods for delivery of therapeutic agents, such as chemically stabilized antisense oligonucleotides useful in RNA silencing. The compositions include interfering nanoparticles (iNOPs) associated with one or more agents. Several functional iNOP derivatives are provided which allow for targeted delivery of agents to specific cell types as well as exhibiting reduced cellular toxicity.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 30, 2018
    Assignee: Sanford-Burnham Medical Research Institute
    Inventor: Tariq M. Rana
  • Protein purification
    Patent number: 9868760
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: January 16, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof
    Patent number: 9856288
    Abstract: Disclosed are a tripeptide epoxyketone compound, a preparation method thereof, and a use thereof in the preparation of anti-tumor drugs.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: January 2, 2018
    Assignees: ZHEJIANG UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Yongzhou Hu, Jia Li, Tao Liu, Jiankang Zhang, Yubo Zhou, Bo Yang, Qiaojun He, Lei Xu, Xiaobei Hu